Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, prostate

1707 - AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer


09 Oct 2016


Genitourinary tumours, prostate


Marzia Del Re


Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372


M. Del Re1, E. Biasco2, S. Crucitta3, L. Derosa2, E. Rofi3, A. Farnesi2, A. Sbrana2, G. Restante1, L. Galli2, A. Falcone2, G. Jenster4, R.H.N. van Schaik5, R. Danesi1

Author affiliations

  • 1 Clinical And Experimental Medicine, University of Pisa, 56126 - Pisa/IT
  • 2 Translational Research And New Technologies In Medicine, University of Pisa, Pisa/IT
  • 3 Clinical And Experimental Medicine, University of Pisa, Pisa/IT
  • 4 Department Of Urology, Erasmus University Medical Center, Rotterdam/NL
  • 5 Department Of Clinical Chemistry, Erasmus University Medical Center, Rotterdam/NL


Abstract 1707


The androgen receptor splice variant 7 (AR-V7) is associated with resistance to hormonal therapy in castration resistant prostate cancer (CRPC). Due to the limitations of methods available for AR-V7 analysis, the identification of a reliable detection method may facilitate the use of this biomarker in clinical practice. In order to provide a reliable laboratory approach to AR-V7 assessment, the present study was conducted to: 1) confirm the role of AR-V7 in prediction of resistance to hormonal therapy; 2) develop a new methodological approach to reliably and easily assess AR-V7 by a digital droplet PCR in exosomal-derived RNA from plasma samples and 3) provide new data to address the correlation between exosomal-derived AR-V7 RNA and resistance, being the translation CTC to exosomes not obvious.


Two ml of plasma samples were collected from 36 CRPC patients before the beginning of second-line hormonal treatment. Exosomes were isolated and RNA extracted for analysis of AR-V7 by digital droplet PCR.


39% of patients were found carriers of the AR-V7 transcript. Twenty-six patients received abiraterone and 10 enzalutamide. The median clinical or radiographic progression free survival was significantly longer in AR-V7 negative compared to positive patients (20 vs 3 months; P 


The present study demonstrates that plasma-derived exosomal RNA is a reliable source of AR-V7 and its detection predicts resistance to anti-hormonal therapy. The method is sensitive, fast and represents a convenient alternative to other potentially more expensive and less sensitive approaches, i.e., circulating tumor cells.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Prof. Romano Danesi


Academic fundings


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings